All Blogs
Jan 11, 2023
Digital Health: Insights Into the Key Transformative Trends & Evolving Market Dynamics
Over the past few years, the digital health market has registered immense growth owing to technological advancements and rising demand from the consumer side for better health outcomes. As per the latest assessment by DelveInsight, owing to several favorable factors, the global digital health market is estimated to...
Read More...
Jan 10, 2023
Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL
Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...
Read More...
Jan 09, 2023
Is it the Dawn of Biologics in the Eosinophilic Esophagitis Treatment Landscape?
Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one’s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are consider...
Read More...
Jan 06, 2023
Osteomyelitis Treatment Market: Evaluating the New Line of Therapies in the Therapeutics Space
A bone marrow infection that tends to spread and frequently involves periosteal tissues and nearby cortical plates is known as osteomyelitis. It might be acute, subacute, or chronic. In most cases, acute osteomyelitis is hematogenous in origin, has a recent onset, and has a brief duration. It can also be brought on...
Read More...
Jan 05, 2023
Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System
Inspira Technologies Signed Strategic OEM Agreement with Terumo Cardiovascular On December 27, 2023, Inspira Technologies, a ground breaking respiratory support technology company, announced that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of...
Read More...
Jan 04, 2023
Insights Into the Evolving Landscape of the Ocular Implants Market
Vision loss or vision impairment is one of the major issues globally that can affect people of all ages. As per the WHO, Globally, about 2.2 billion people have a near or distance vision impairment. Moreover, in almost half of the cases, vision impairment could have been prevented or has yet to be addressed. It is ...
Read More...
Jan 03, 2023
Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi
Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...
Read More...
Aug 20, 2025
ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions
ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...
Read More...
Dec 30, 2022
Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management
Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...
Read More...
Dec 29, 2022
PAVmed-Novosound’s Partnership; J&J Acquires Abiomed; Approval to Sysmex’s Assay Kit to Identify Amyloid Beta (Aβ) Accumulation; SI-BONE Announced FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite Implant System; EOFlow’s Wearable Insulin Pump ‘EOPatch’; Icecure’s ProSense System, a Cryoablation Therapy
PAVmed Entered into a Partnership with Novosound for Ultrasound Imaging Technology On December 22, 2022, PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that the company has entered into a partnership with...
Read More...